Skip to main content Skip to section navigation Skip to footer
Rezolute, Inc. IR Overview
  • About
    • Our Mission
    • Leadership
    • Board of Directors
  • Our Science
  • Pipeline
    • Overview
    • Congenital Hyperinsulinism
    • Tumor Hyperinsulinism
  • Publications
    • Publications
    • Data Presentations
  • For Patients
  • Join Us
    • Values
    • Benefits
    • Open Positions
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News
    • Events
    • Stock Quote and Chart
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info
  • Contact Us

News

Investors

Investors

  • Overview
  • Corporate Presentation
  • News
  • Events
  • Stock Quote and Chart
  • Historical Data
  • Analyst Coverage
  • SEC Filings
  • Governance
    • Governance Documents
  • Info
Jan 24, 2024 8:00 am EST
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
Jan 23, 2024 8:00 am EST
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Dec 14, 2023 8:00 am EST
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
Dec 13, 2023 8:00 am EST
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
Nov 17, 2023 8:00 am EST
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
Nov 13, 2023 4:05 pm EST
Rezolute Reports First Quarter Fiscal 2024 Results
Oct 17, 2023 8:00 am EDT
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
Oct 11, 2023 8:00 am EDT
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
Sep 14, 2023 4:05 pm EDT
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
Sep 6, 2023 7:00 am EDT
Rezolute to Participate in Upcoming Investor Conferences in September
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 16
  • Next Pagearrow_forward
rss_feed News RSS

Stay Connected

  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
Visit us on LinkedIn Visit us on X Visit us on Facebook
rezolute logo

©2025 Rezolute, Inc.

Explore

  • About
  • Approach
  • Pipeline
  • Publications
  • For Patients
  • Join Us
  • Investors & Media
  • Contact Us

Contact

Corporate Headquarters

275 Shoreline Drive
Suite 500
Redwood City, CA 94065

+1 (650) 206-4507
info@rezolutebio.com

Investor Relations

Oregon Office
2783 NW Lolo Drive
Suite 150
Bend, OR 97703

Legal

  • Terms of Use
  • Privacy Policy
MENU
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Approach
    • Overview
    • Congenital Hyperinsulinism
    • Tumor Hyperinsulinism
    • Additional Programs
  • Pipeline
    • Overview
    • Congenital Hyperinsulinism
    • Tumor Hyperinsulinism
    • Additional Programs
  • Publications
    • Publications
    • Data Presentations
  • For Patients
  • Join Us
    • Values
    • Benefits
    • Open Positions
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News
    • Events
    • Stock Quote and Chart
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info
  • Contact Us